Elaine Shum

1.5k total citations
52 papers, 586 citations indexed

About

Elaine Shum is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Elaine Shum has authored 52 papers receiving a total of 586 indexed citations (citations by other indexed papers that have themselves been cited), including 41 papers in Pulmonary and Respiratory Medicine, 39 papers in Oncology and 9 papers in Molecular Biology. Recurrent topics in Elaine Shum's work include Lung Cancer Treatments and Mutations (33 papers), Colorectal Cancer Treatments and Studies (12 papers) and Cancer Immunotherapy and Biomarkers (12 papers). Elaine Shum is often cited by papers focused on Lung Cancer Treatments and Mutations (33 papers), Colorectal Cancer Treatments and Studies (12 papers) and Cancer Immunotherapy and Biomarkers (12 papers). Elaine Shum collaborates with scholars based in United States, Japan and South Korea. Elaine Shum's co-authors include Haiying Cheng, Balázs Halmos, Román Pérez-Soler, Vamsidhar Velcheti, Salman R. Punekar, Sally C. M. Lau, Pasi A. Jänne, Lei Wang, Suresh S. Ramalingam and Shirish M. Gadgeel and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer Research.

In The Last Decade

Elaine Shum

51 papers receiving 582 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Elaine Shum United States 13 388 348 176 78 69 52 586
Manuel Ruíz Borrego Spain 12 369 1.0× 242 0.7× 178 1.0× 66 0.8× 166 2.4× 59 537
Katherine Minichiello United States 9 389 1.0× 298 0.9× 136 0.8× 57 0.7× 121 1.8× 20 527
Linda Mahjoubi France 9 369 1.0× 208 0.6× 213 1.2× 113 1.4× 132 1.9× 12 558
Trine Lindsted United States 7 254 0.7× 158 0.5× 208 1.2× 86 1.1× 91 1.3× 10 439
Christie J. Lau United States 10 264 0.7× 288 0.8× 148 0.8× 65 0.8× 159 2.3× 14 503
M. D’Arcangelo Italy 12 200 0.5× 196 0.6× 119 0.7× 41 0.5× 79 1.1× 31 360
Sonya C. Chapman United States 10 412 1.1× 363 1.0× 65 0.4× 85 1.1× 86 1.2× 17 552
Davide Bosso Italy 12 132 0.3× 167 0.5× 133 0.8× 41 0.5× 70 1.0× 18 366
Bin-Chao Wang China 9 386 1.0× 426 1.2× 133 0.8× 31 0.4× 172 2.5× 21 560

Countries citing papers authored by Elaine Shum

Since Specialization
Citations

This map shows the geographic impact of Elaine Shum's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Elaine Shum with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Elaine Shum more than expected).

Fields of papers citing papers by Elaine Shum

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Elaine Shum. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Elaine Shum. The network helps show where Elaine Shum may publish in the future.

Co-authorship network of co-authors of Elaine Shum

This figure shows the co-authorship network connecting the top 25 collaborators of Elaine Shum. A scholar is included among the top collaborators of Elaine Shum based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Elaine Shum. Elaine Shum is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Heist, Rebecca S., Elaine Shum, Esther García Pagès, et al.. (2025). MYTX-011, a cMET-targeting antibody-drug conjugate (ADC), in patients with previously treated, advanced NSCLC: Updated dose escalation results in the phase 1 KisMET-01 study.. Journal of Clinical Oncology. 43(16_suppl). 8613–8613. 1 indexed citations
2.
3.
4.
Shum, Elaine, Wei Li, Jimmy D. Bell, et al.. (2023). OA16.04 Preliminary Results from the Female Asian Nonsmoker Screening Study (FANSS). Journal of Thoracic Oncology. 18(11). S81–S82. 1 indexed citations
5.
Ohri, Nitin, Shruti Jolly, Benjamin T. Cooper, et al.. (2023). Selective Personalized RadioImmunotherapy for Locally Advanced Non–Small-Cell Lung Cancer Trial (SPRINT). Journal of Clinical Oncology. 42(5). 562–570. 25 indexed citations
6.
Kitazono, Satoru, Luis Paz‐Ares, M-J. Ahn, et al.. (2023). 518MO TROPION-Lung05: Datopotamab deruxtecan (Dato-DXd) in previously treated non-small cell lung cancer (NSCLC) with actionable genomic alterations (AGAs). Annals of Oncology. 34. S1671–S1672. 8 indexed citations
7.
Paz‐Ares, Luis, M-J. Ahn, Aaron Lisberg, et al.. (2023). 1314MO TROPION-Lung05: Datopotamab deruxtecan (Dato-DXd) in previously treated non-small cell lung cancer (NSCLC) with actionable genomic alterations (AGAs). Annals of Oncology. 34. S755–S756. 30 indexed citations
8.
Piotrowska, Zofia, Elaine Shum, Ying Liu, et al.. (2023). Tissue and plasma-based mechanisms of resistance to first-line osimertinib in EGFR-mutant NSCLC: A multi-institutional cohort.. Journal of Clinical Oncology. 41(16_suppl). 9108–9108. 4 indexed citations
9.
Le, Xiuning, Elaine Shum, Christina S. Baik, et al.. (2023). LBA71 A multi-centre open-label randomized phase II study of osimertinib with and without ramucirumab in TKI-naïve EGFR-mutant metastatic NSCLC (RAMOSE trial interim analysis). Annals of Oncology. 34. S1313–S1314. 8 indexed citations
10.
Lee, Jay M., Ciaran McNamee, Eric M. Toloza, et al.. (2023). Neoadjuvant Targeted Therapy in Resectable NSCLC: Current and Future Perspectives. Journal of Thoracic Oncology. 18(11). 1458–1477. 36 indexed citations
11.
Zhang, Shannon, Misako Nagasaka, Joseph J. Zhao, et al.. (2023). Low-Dose Computed Tomography (LDCT) Lung Cancer Screening in Asian Female Never-Smokers Is as Efficacious in Detecting Lung Cancer as in Asian Male Ever-Smokers: A Systematic Review and Meta-Analysis. Journal of Thoracic Oncology. 18(6). 698–717. 22 indexed citations
12.
Li, Xiaochun, James W. Smithy, Allison Betof Warner, et al.. (2022). Examination of speakership gender disparity at an international oncology conference.. Journal of Clinical Oncology. 40(16_suppl). 11002–11002. 1 indexed citations
13.
Veluswamy, Rajwanth, Sheena Bhalla, Robert Samstein, et al.. (2022). 1018P Phase I/II trial of rigosertib and nivolumab for KRAS mutated non-small cell lung cancer (NSCLC) patients. Annals of Oncology. 33. S1019–S1020. 2 indexed citations
14.
Sacher, Adrian G., Xiuning Le, Robin Cornelissen, et al.. (2021). 36MO Safety, tolerability and preliminary efficacy of poziotinib with twice daily strategy in EGFR/HER2 Exon 20 mutant non-small cell lung cancer. Annals of Oncology. 32. S15–S15. 19 indexed citations
15.
Gutierrez, Martin, Filip Jankú, Linjie Tian, et al.. (2021). A phase 1/2, open-label, dose-escalation, safety and tolerability study of NC410 in subjects with advanced or metastatic solid tumors.. Journal of Clinical Oncology. 39(15_suppl). TPS2659–TPS2659. 2 indexed citations
16.
Hellmann, Matthew D., Pasi A. Jänne, Mateusz Opyrchal, et al.. (2020). Entinostat plus Pembrolizumab in Patients with Metastatic NSCLC Previously Treated with Anti–PD-(L)1 Therapy. Clinical Cancer Research. 27(4). 1019–1028. 83 indexed citations
17.
Ohri, Nitin, Haiying Cheng, Shruti Jolly, et al.. (2019). The selective personalized radioimmunotherapy for locally advanced NSCLC trial (SPRINT).. Journal of Clinical Oncology. 37(15_suppl). TPS8571–TPS8571. 10 indexed citations
18.
Shum, Elaine, et al.. (2017). Emerging treatment using tubulin inhibitors in advanced non-small cell lung cancer. Expert Opinion on Pharmacotherapy. 18(7). 701–716. 41 indexed citations
19.
Shum, Elaine, et al.. (2016). The Evolving Role of Biomarkers in Personalized Lung Cancer Therapy. Respiration. 93(1). 1–14. 6 indexed citations
20.
Shum, Elaine, et al.. (2015). More than a headache: a case of cetuximab-induced aseptic meningitis. BMJ Case Reports. 2015. bcr2015209622–bcr2015209622. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Manuel Ruíz Borrego Breakdown of academic impact, for papers by Katherine Minichiello Breakdown of academic impact, for papers by Linda Mahjoubi Breakdown of academic impact, for papers by Trine Lindsted Breakdown of academic impact, for papers by Christie J. Lau Breakdown of academic impact, for papers by M. D’Arcangelo Breakdown of academic impact, for papers by Sonya C. Chapman Breakdown of academic impact, for papers by Davide Bosso Breakdown of academic impact, for papers by Bin-Chao Wang
Rankless by CCL
2026